Loading candles…
Aarti Pharmalabs Ltd was incorporated in 2019 through a demerger from Aarti Industries Limited. The company operates in the pharmaceuticals and nutraceuticals industries, specializing in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, xanthine derivatives, pharmaceuticals, and nutraceuticals. It provides end-to-end solutions from process development to commercial manufacturing. Aarti Pharmalabs maintains a strong global presence with exports to regulated markets including India, the United States, the European Union, and Japan. The company is recognized as a key player in the 'China+1' strategy, utilizing fully backward-integrated manufacturing processes to enhance supply chain resilience.
This page is a live market overview for AARTI PHARMALABS LIMITED (AARTIPHARM) on the NSE. As a listed security, AARTI PHARMALABS LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AARTIPHARM before placing trades on tick2trade.
As of the latest feed, AARTIPHARM last traded at ₹685.85 on NSE, down ₹6.4 (0.92%) from the previous close of ₹692.25. Today's session range is ₹683 – ₹706, against a 52-week band of ₹585 – ₹946.1. Traded volume today stands at 1.80L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for AARTIPHARM in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AARTIPHARM is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for AARTI PHARMALABS LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AARTIPHARM. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AARTIPHARM option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 7 Aug 2026 |
| Results - FY26 | AARTIPHARM : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 18, 2026 has been re-scheduled. Further, the Company… | 25 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 18 May 2026 |
| Unaudited Results - Q3-FY25 | AARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 09-Feb-2026 to consider and approve the Quarterly Unaudited Financial re… | 9 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the unaudited standalone and consolidated financial results for the period ended September 30, 2025 | 9 Nov 2025 |
| Unaudited Results - FY25 | To consider and approve the unaudited financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 10 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.